Replies to post #130336 on Biotech Values

[oc631]

Why would DEB025 have to be relegated to the second- or third-line setting? If it can add modest efficacy to a nuke-based regimen with no increase in resistance, I see no reason why DEB025 is unsuited to the first-line setting.

I agree with you its possible and I obviously am not being clear in my original statement. It could see first-line usage in future treatment if mutation within the nuke class became an issue. I don't see this as being a problem in the developed world.